Article info

Download PDFPDF

Response to: ‘Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’’ by Satis et al
Free

Authors

  1. Correspondence to Dr Seza Ozen, Pediatric Rheumatology, Hacettepe University, Ankara 06800, Turkey; sezaozen{at}gmail.com
View Full Text

Citation

Ozen S, De Benedetti F
Response to: ‘Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’’ by Satis et al

Publication history

  • Received August 28, 2020
  • Accepted August 30, 2020
  • First published September 28, 2020.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.